Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiota and Metabolomic Changes with Rifaximin in IBS-D
NCT03557788Phase 4Completed
- Sponsor
- National University Hospital
- Start
- May 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rifaximin in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by National University Hospital. Primary endpoint: IBS Symptom Severity Score at Day 90. Started May 2018; status: completed.
02
Drugs
rifaximin
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT03557788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557788.